Efficacy and Safety of Benralizumab in Paediatric Patients with Severe Eosinophilic Asthma (DOMINICA)
6 Years - 18 Years
Endpoint Classification: -
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
Verified 01 Nov 2023 by AstraZeneca
No locations available
Patients will receive Benralizumab as an active solution via a subcutaneous (SC) injection.
Benralizumab active solution will be administered SC to the patients.
|Placebo Comparator: Placebo|
Patients will receive a matching solution of the placebo via SC injection.
Placebo solution will be administered SC to the patients.